Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 809Neoplasms, Plasma Cell 111Recurrence 109Immunoglobulin Light-chain Amyloidosis 50Neoplasms 33Amyloidosis 21Smoldering Multiple Myeloma 15Renal Insufficiency 13Paraproteinemias 12Lymphoma, Non-Hodgkin 12Hematologic Diseases 11Leukemia, Plasma Cell 10Lymphoma 9Plasmacytoma 8Leukemia, Myeloid, Acute 7Hematologic Neoplasms 7Disease 6Blood Protein Disorders 6Lymphoma, Large B-Cell, Diffuse 5Leukemia, Lymphocytic, Chronic, B-Cell 5Leukemia 5Hodgkin Disease 5Neoplasm, Residual 4Nausea 4Myelodysplastic Syndromes 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Disease Progression 4Chromosome 17 deletion 4

Interventions

Lenalidomide 2Dexamethasone 2Bortezomib 2carfilzomib 1belinostat 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Bone Marrow Neoplasms × Dexamethasone × Plasma cell × Clear all
NCT03859427 2024-08-13

ARROW2

Amgen

Phase 3 Completed
454 enrolled 24 charts
Plasma cell

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

NCT00908232 2015-01-15

SEQUENTIAL

Janssen-Cilag International NV

Phase 2 Completed
163 enrolled 11 charts
Plasma cell

Multiple Myeloma, Disease Progression, Bone Marrow Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡